Cargando…
Narrative review of metabolomics in cardiovascular disease
Cardiovascular diseases are accompanied by disorders in the cardiac metabolism. Furthermore, comorbidities often associated with cardiovascular disease can alter systemic and myocardial metabolism contributing to worsening of cardiac performance and health status. Biomarkers such as natriuretic pept...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107570/ https://www.ncbi.nlm.nih.gov/pubmed/34012599 http://dx.doi.org/10.21037/jtd-21-22 |
_version_ | 1783689982007836672 |
---|---|
author | Müller, Julian Bertsch, Thomas Volke, Justus Schmid, Alexander Klingbeil, Rebecca Metodiev, Yulian Karaca, Bican Kim, Seung-Hyun Lindner, Simon Schupp, Tobias Kittel, Maximilian Poschet, Gernot Akin, Ibrahim Behnes, Michael |
author_facet | Müller, Julian Bertsch, Thomas Volke, Justus Schmid, Alexander Klingbeil, Rebecca Metodiev, Yulian Karaca, Bican Kim, Seung-Hyun Lindner, Simon Schupp, Tobias Kittel, Maximilian Poschet, Gernot Akin, Ibrahim Behnes, Michael |
author_sort | Müller, Julian |
collection | PubMed |
description | Cardiovascular diseases are accompanied by disorders in the cardiac metabolism. Furthermore, comorbidities often associated with cardiovascular disease can alter systemic and myocardial metabolism contributing to worsening of cardiac performance and health status. Biomarkers such as natriuretic peptides or troponins already support diagnosis, prognosis and treatment of patients with cardiovascular diseases and are represented in international guidelines. However, as cardiovascular diseases affect various pathophysiological pathways, a single biomarker approach cannot be regarded as ideal to reveal optimal clinical application. Emerging metabolomics technology allows the measurement of hundreds of metabolites in biological fluids or biopsies and thus to characterize each patient by its own metabolic fingerprint, improving our understanding of complex diseases, significantly altering the management of cardiovascular diseases and possibly personalizing medicine. This review outlines current knowledge, perspectives as well as limitations of metabolomics for diagnosis, prognosis and treatment of cardiovascular diseases such as heart failure, atherosclerosis, ischemic and non-ischemic cardiomyopathy. Furthermore, an ongoing research project tackling current inconsistencies as well as clinical applications of metabolomics will be discussed. Taken together, the application of metabolomics will enable us to gain more insights into pathophysiological interactions of metabolites and disease states as well as improving therapies of patients with cardiovascular diseases in the future. |
format | Online Article Text |
id | pubmed-8107570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-81075702021-05-18 Narrative review of metabolomics in cardiovascular disease Müller, Julian Bertsch, Thomas Volke, Justus Schmid, Alexander Klingbeil, Rebecca Metodiev, Yulian Karaca, Bican Kim, Seung-Hyun Lindner, Simon Schupp, Tobias Kittel, Maximilian Poschet, Gernot Akin, Ibrahim Behnes, Michael J Thorac Dis Review Article Cardiovascular diseases are accompanied by disorders in the cardiac metabolism. Furthermore, comorbidities often associated with cardiovascular disease can alter systemic and myocardial metabolism contributing to worsening of cardiac performance and health status. Biomarkers such as natriuretic peptides or troponins already support diagnosis, prognosis and treatment of patients with cardiovascular diseases and are represented in international guidelines. However, as cardiovascular diseases affect various pathophysiological pathways, a single biomarker approach cannot be regarded as ideal to reveal optimal clinical application. Emerging metabolomics technology allows the measurement of hundreds of metabolites in biological fluids or biopsies and thus to characterize each patient by its own metabolic fingerprint, improving our understanding of complex diseases, significantly altering the management of cardiovascular diseases and possibly personalizing medicine. This review outlines current knowledge, perspectives as well as limitations of metabolomics for diagnosis, prognosis and treatment of cardiovascular diseases such as heart failure, atherosclerosis, ischemic and non-ischemic cardiomyopathy. Furthermore, an ongoing research project tackling current inconsistencies as well as clinical applications of metabolomics will be discussed. Taken together, the application of metabolomics will enable us to gain more insights into pathophysiological interactions of metabolites and disease states as well as improving therapies of patients with cardiovascular diseases in the future. AME Publishing Company 2021-04 /pmc/articles/PMC8107570/ /pubmed/34012599 http://dx.doi.org/10.21037/jtd-21-22 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Müller, Julian Bertsch, Thomas Volke, Justus Schmid, Alexander Klingbeil, Rebecca Metodiev, Yulian Karaca, Bican Kim, Seung-Hyun Lindner, Simon Schupp, Tobias Kittel, Maximilian Poschet, Gernot Akin, Ibrahim Behnes, Michael Narrative review of metabolomics in cardiovascular disease |
title | Narrative review of metabolomics in cardiovascular disease |
title_full | Narrative review of metabolomics in cardiovascular disease |
title_fullStr | Narrative review of metabolomics in cardiovascular disease |
title_full_unstemmed | Narrative review of metabolomics in cardiovascular disease |
title_short | Narrative review of metabolomics in cardiovascular disease |
title_sort | narrative review of metabolomics in cardiovascular disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107570/ https://www.ncbi.nlm.nih.gov/pubmed/34012599 http://dx.doi.org/10.21037/jtd-21-22 |
work_keys_str_mv | AT mullerjulian narrativereviewofmetabolomicsincardiovasculardisease AT bertschthomas narrativereviewofmetabolomicsincardiovasculardisease AT volkejustus narrativereviewofmetabolomicsincardiovasculardisease AT schmidalexander narrativereviewofmetabolomicsincardiovasculardisease AT klingbeilrebecca narrativereviewofmetabolomicsincardiovasculardisease AT metodievyulian narrativereviewofmetabolomicsincardiovasculardisease AT karacabican narrativereviewofmetabolomicsincardiovasculardisease AT kimseunghyun narrativereviewofmetabolomicsincardiovasculardisease AT lindnersimon narrativereviewofmetabolomicsincardiovasculardisease AT schupptobias narrativereviewofmetabolomicsincardiovasculardisease AT kittelmaximilian narrativereviewofmetabolomicsincardiovasculardisease AT poschetgernot narrativereviewofmetabolomicsincardiovasculardisease AT akinibrahim narrativereviewofmetabolomicsincardiovasculardisease AT behnesmichael narrativereviewofmetabolomicsincardiovasculardisease |